Related references
Note: Only part of the references are listed.Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy
Suthinee Ithimakin et al.
SUPPORTIVE CARE IN CANCER (2020)
Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review
Abu Saleh Mohammad Mosa et al.
FRONTIERS IN PHARMACOLOGY (2020)
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy
Takako Yanai et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Evaluation of a neurokinin-1 antagonist in preventing multiple-day cisplatin-induced nausea and vomiting
Quanfu Li et al.
OPEN MEDICINE (2018)
Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study
G. Shivaprakash et al.
INDIAN JOURNAL OF PHARMACOLOGY (2017)
Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?
Terry L. Ng et al.
ONCOLOGIST (2015)
Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting
Rudolph M. Navari
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy
H. F. Gao et al.
INTERNAL MEDICINE JOURNAL (2013)
Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study
Costantine Albany et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Lijun Tan et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall
AR Martin et al.
SUPPORTIVE CARE IN CANCER (2003)
Effects of the neurolunin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone
JB McCrea et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Share Paper
